Abstract
A large number of systemically administered drugs have the potential to cause drug-induced interstitial lung disease (DIILD). We aim to characterize a model of DIILD in the rat and develop imaging biomarkers (IBs) for detection and quantification of DIILD. In this study, Sprague–Dawley rats received one single dose of intratracheal (i.t.) bleomycin and were longitudinally imaged at day 0, 3, 7, 14, 21, and 28 post dosing, applying the imaging techniques magnetic resonance imaging (MRI) and positron emission tomography (PET)/computed tomography (CT). Bronchoalveolar lavage fluid (BALF) was analyzed for total protein and inflammatory cells. Lungs were saved for further evaluation by gene analysis using quantitative-PCR and by histology. Lung sections were stained with Masson’s-Trichrome staining and evaluated by modified Ashcroft score. Gene expression profiling of inflammatory and fibrotic markers was performed on lung tissue homogenates. Bleomycin induced significant increase in total protein concentration and total cell count in bronchoalveolar lavage (BAL), peaking at day 3 (p > 0.001) and day 7 (p > 0.001) compared to control, respectively. Lesions measured by MRI and PET signal in the lungs of bleomycin challenged rats were significantly increased during days 3–14, peaking at day 7. Two subgroups of animals were identified as low- and high-responders by their different change in total lung volume. Both groups showed signs of inflammation initially, while at later time points, the low-responder group recovered toward control, and the high-responder group showed sustained lung volume increase, and significant increase of lesion volume (p < 0.001) compared to control. Lastly, important inflammatory and pro-fibrotic markers were assessed from lung tissue, linking observed imaging pathological changes to gene expression patterns. In conclusion, bleomycin-induced lung injury is an adequate animal model for DIILD studies and for translational lung injury assessment by MRI and PET imaging. The scenario comprised disease responses, with different fractions of inflammation and fibrosis. Thereby, this study improved the understanding of imaging and biological biomarkers in DIILD and lung injury.
Highlights
Many drugs generate more or less severe adverse effects, affecting one or several organs depending on the type of drug, dosing, and administrative route
When adverse effects afflict the lung upon drug administration, the interstitium is harmed inducing druginduced interstitial lung disease (DIILD), a disease that in the worst case can progress into lung failure, chronic fibrosis, and death (Flieder and Travis, 2004; Schwaiblmair et al, 2012; Delaunay et al, 2017)
Drug-induced interstitial lung disease is a form of ILD, caused by drugs and not associated with environmentally induced damage caused by inhaled agent(s) (Travis et al, 2013; Antoniou et al, 2014)
Summary
Many drugs generate more or less severe adverse effects, affecting one or several organs depending on the type of drug, dosing, and administrative route. Different drugs can induce very different pathophysiologies, and other already present pathological conditions in the lung may hamper the diagnosis of DIILD (Camus et al, 2004; Skeoch et al, 2018). There is not one single characteristic pathophysiological or specific radiological pattern for how this disease manifests itself, but rather a number of different appearances in which it can be manifested (Travis et al, 2013; Skeoch et al, 2018)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
